Page last updated: 2024-12-08

bis(diazo)benzidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bis(diazo)benzidine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID192776
SCHEMBL ID13567593
MeSH IDM0049512

Synonyms (8)

Synonym
5957-03-9
4,4'-biphenylbis(diazonium)
bis(diazo)benzidine
(1,1'-biphenyl)-4,4'-bis(diazonium)
bis-diazotized benzidine
[1,1'-biphenyl]-4,4'-bis(diazonium)
SCHEMBL13567593
DTXSID40974973

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" However, drug candidates exhibiting PTP1B selectivity and oral bioavailability are currently lacking."( Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides.
Guo, S; Jiang, B; Li, C; Li, X; Luo, J; Shi, D; Wang, L; Yu, R; Zheng, M, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (68.00)18.7374
1990's2 (8.00)18.2507
2000's0 (0.00)29.6817
2010's1 (4.00)24.3611
2020's5 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.45 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (96.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]